3.11
-0.03
(-0.96%)
May 23 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 3.05 - 3.14 |
| 52 week | 2.47 - 4.59 |
| Open | 3.10 |
| Vol / Avg. | 128,643.00/153,464.00 |
| Mkt cap | 90.40M |
| P/E | - |
| Div/yield | - |
| EPS | -2.42 |
| Shares | 29.07M |
| Beta | - |
| Inst. own | 53% |
Events
May 14, 2013
Q1 2013 Nupathe Inc Earnings Conference Call
Mar 26, 2013
Q4 2012 Nupathe Inc Earnings Conference Call
|
More events from DailyFinance »
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -117.28% | -79.84% |
| Return on average equity | - | -865.71% |
| Employees | 14 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 200, 227 Washington Street
CONSHOHOCKEN, PA 19428
United States - Map
+1-484-5670130 (Phone)
+1-484-5670136 (Fax)
CONSHOHOCKEN, PA 19428
United States - Map
+1-484-5670130 (Phone)
+1-484-5670136 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
NuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. The Companys products are NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company completed a pivotal Phase III clinical trial for Zelrix, an active, single-use transdermal sumatriptan patch for the treatment of acute migraine.
Officers and directors
| Wayne P. Yetter | Independent Chairman of the Board | |
| Terri B. Sebree | President | |
| Armando Anido | Chief Executive Officer, Director | |
| Keith Alan Goldan CPA | Vice President and Chief Financial Officer | |
| Gerald W. McLaughlin | Vice President - Commercial Operations | |
| Michael F. Marino | Vice President, General Counsel, Secretary | |
| Bart J. Dunn | Vice President - Corporate Development and Licensing | |
| James A. Datin | Director | |
| Richard S. Kollender | Director | |
| Brian J. Sisko | Director |